BCRX Q1 2019 Earnings — BioCryst Pharmaceuticals, Inc. Revenue & Financial Results | Market Cap Arena

BCRXBioCryst Pharmaceuticals, Inc.

$2B

Q1 2019 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$6M+48.1% YoY

Gross Profit

$4M74.8% margin

Operating Income

-$29M-498.2% margin

Net Income

-$31M-527.5% margin

EPS (Diluted)

$-0.28

QoQ Revenue Growth

+115.7%

Cash Flow

Operating Cash Flow

-$27M

Free Cash Flow

-$27M

Stock-Based Comp.

$3M

Balance Sheet

Total Assets

$142M

Total Liabilities

$120M

Stockholders' Equity

$23M

Cash & Equivalents

$35M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$6M	$4M	+48.1%
Gross Profit	$4M	$4M	+14.7%
Operating Income	-$29M	-$22M	-32.0%
Net Income	-$31M	-$26M	-20.5%

Revenue Segments

Royalty

$2M39%

Collaborative and Other Research and Development

$2M32%

Product

$2M29%